1

Lowered oxygen saturation and increased body temperature in acute COVID-19 largely predict chronic fatigue syndrome and affective symptoms due to LONG COVID: a precision nomothetic approach

Dhurgham Shihab Al-Hadrawi <sup>a</sup>, Haneen Tahseen Al-Rubaye <sup>b</sup>, Abbas F. Almulla <sup>c,e</sup>, Hussein Kadhem Al-Hakeim <sup>d</sup>, Michael Maes <sup>e,f,g \*</sup>

<sup>a</sup> Al-Najaf Center for Cardiac Surgery and Transcatheter Therapy. Email:

Durgham2512@gamil.com

<sup>b</sup> College of Medical laboratory Techniques, Imam Ja'afar Al-Sadiq University, Najaf, Iraq. Email: haneent033@gmail.com

<sup>c</sup> Medical Laboratory Technology Department, College of Medical Technology, The Islamic University, Najaf, Iraq. E-mail: <u>abbass.chem.almulla1991@gmail.com</u>

<sup>d</sup> Department of Chemistry, College of Science, University of Kufa, Iraq. E-mail: headm2010@yahoo.com.

<sup>e</sup> Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

<sup>f</sup> Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria

<sup>g</sup> Deakin University, IMPACT, the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Australia.

\* Corresponding Author:

Prof. Dr. Michael Maes, M.D., Ph.D.

Department of Psychiatry

Faculty of Medicine

King Chulalongkorn Memorial Hospital

Bangkok, Thailand

E-mail: dr.michaelmaes@hotmail.com.

(4) Michael Maes (researchgate.net)

Michael Maes - Google Scholar

3

## Abstract

**Background:** Long coronavirus disease 2019 (LC) is a chronic sequel of acute COVID-19. The exact pathophysiology of the affective, chronic fatigue and physiosomatic symptoms (labeled as "physio-affective phenome") of LC has remained elusive.

**Objective:** The current study aims to delineate the effects of oxygen saturation (SpO2) and body temperature during the acute phase on the physio-affective phenome of LC.

**Method:** We recruited 120 LC patients and 36 controls. For all participants, we assessed the lowest SpO2 and peak body temperature during acute COVID-19, and the Hamilton Depression and Anxiety Rating Scale (HAMD/HAMA) and Fibro Fatigue (FF) scales 3 to 4 months later.

**Results:** Lowered SpO2 and increased body temperature during the acute phase and female sex predict 60.7% of the variance in the physio-affective phenome of LC. Using unsupervised learning techniques we were able to delineate a new endophenotype class, which comprises around 26.7% of the LC patients and is characterized by very low SpO2 and very high body temperature, and depression, anxiety, chronic fatigue, and autonomic and gastro-intestinal symptoms scores. Single latent vectors could be extracted from both biomarkers, depression, anxiety and FF symptoms or from both biomarkers, insomnia, chronic fatigue, gastro-intestinal and autonomic symptoms.

**Conclusion:** The newly constructed endophenotype class and pathway phenotypes indicate that the physio-affective phenome of LC is at least in part the consequence of the pathophysiology of acute COVID-19, namely the combined effects of lowered SpO2, increased body temperature and the associated immune-inflammatory processes and lung lesions.

**Keywords:** Long COVID-19, Hypoxia, Depression, Chronic fatigue syndrome, Inflammation, Psychiatry, Neuro-immune

4

### Introduction

Long coronavirus disease 2019 or post-corona virus disease 2019 (post-COVID-19 or Long COVID) is a sequel of prior infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Nalbandian, Sehgal et al. 2021, World Health Organization 2022). This syndrome is manifested as a cluster of symptoms mainly but not limited to fatigue, shortening of breath, persistent cough, chest pain, cognitive impairments, and affective symptoms (Renaud-Charest, Lui et al. 2021, Sandler, Wyller et al. 2021, Titze-de-Almeida, da Cunha et al. 2022). Similar consequences were also reported in previous epidemics, for example SARS-2003 and the Middle East respiratory syndrome (MERS-2012) (Lam, Wing et al. 2009, Moldofsky and Patcai 2011, Lee, Shin et al. 2019, Ahmed, Patel et al. 2020).

There is a growing concern that Long COVID is becoming a serious health issue (Phillips and Williams 2021). Six months after the acute infection, 33% of COVID-19 patients may experience serious neuropsychiatric symptoms, while 13% of them even received a first diagnosis months after the acute phase (Taquet, Geddes et al. 2021). Regardless of whether COVID-19 patients were symptomatic or asymptomatic during the acute phase of illness, 10-20% of them will experience Long COVID symptoms within weeks to months after recovery (Huang, Pinto et al. 2021, World Health Organization 2022). Other results show that 80% of the recovered COVID-19 patients suffer from at least one of the Long COVID symptoms, including fatigue, memory impairment, anxiety and depression (Lopez-Leon, Wegman-Ostrosky et al. 2021, Badenoch, Rengasamy et al. 2022). Interestingly, the prevalence of Long COVID is not affected by hospitalization status, disease severity, or length of follow-up (Davido, Seang et al. 2020, Badenoch, Rengasamy et al. 2022).

5

Acute SARS-CoV-2 infection is characterized by an exaggerated immune-inflammatory response and infiltration of the inflammatory mediators including pro-inflammatory cytokines into the lung tissues (Mehta, McAuley et al. 2020, Pelaia, Tinello et al. 2020, Al-Jassas, Al-Hakeim et al. 2022). The consequent lung injuries, which may be identified by chest computerized tomography abnormalities (CCTAs), are accompanied by lowered oxygen saturation (SpO<sub>2</sub>) which may aggravate the inflammatory responses and may persist even after full recovery (Solomon, Heyman et al. 2021, Vijayakumar, Tonkin et al. 2021, Al-Jassas, Al-Hakeim et al. 2022). Increased body temperature in the acute phase of illness is one of the most common signs of infection and inflammation and this marker is widely used to detect febrile SARS-CoV-2 individuals (Lippi et al., 2021). The degree of increments in body temperature reflect the severity of inflammation and the peak body temperature during the acute phase is associated with an increased mortality risk (Tharakan, Nomoto et al. 2020).

The onset of Long COVID is attributed to precipitating factors associated with SARS-CoV-2 infection including abnormal immune responses, inflammatory damage, alterations in microbiome/virome in response to viral interactions, hypercoagulability, abnormal signaling of the brainstem and vagus nerve, and even physical adaptations to inactivity or psychological factors (Calabrese 2020, Deng, Zhou et al. 2021, Nalbandian, Sehgal et al. 2021, Proal and VanElzakker 2021). Furthermore, the onset of Long COVID fatigue was attributed to predisposing genetic and psychosocial vulnerabilities, and its socio-economic consequences, and perpetuating factors such as sleep disturbances, autonomic dysfunctions, and aberrations in endocrine functions (Theorell, Blomkvist et al. 1999, Papadopoulos and Cleare 2011, Jackson and Bruck 2012, Piraino, Vollmer-Conna et al. 2012, Cvejic, Li et al. 2019, Nelson, Bahl et al. 2019, Sandler, Wyller et al. 2021).

6

functions (Boldrini, Canoll et al. 2021), which may be due to neuroinflammation or the direct effect of hypoxia (Solomon 2021, Song, Zhang et al. 2021).

Nonetheless, no studies examined the effects of acute COVID-19 biomarkers, such as lowered SpO2 and increased body temperature, on the mental and chronic fatigue symptoms during Long COVID. Hence, the aim of this study is to delineate the effects of SpO<sub>2</sub> and body temperature during the acute phase on chronic fatigue syndrome and affective symptoms in Long COVID. In the current study, we use the precision nomothetic approach (Maes 2022) to delineate new pathway phenotypes and endophenotype classes which combine those two infection biomarkers with Long COVID mental and chronic fatigue symptoms. Such data are needed to understand the pathophysiology of Long COVID and post-viral symptoms in general and may help to predict who will develop chronic fatigue syndrome and affective symptoms due to COVID-19 and viral infections in general.

#### **Participants and Methods**

### **Participants**

In the present study, we used a case-control study design (to examine differences between controls and Long COVID subtypes) as well as a retrospective cohort study design (to examine the effects of acute phase biomarkers on Long COVID symptoms). During the last three months of 2021, we recruited 120 participants who suffered from at least 2 symptoms of Long COVID and who were previously diagnosed and treated for acute COVID-19 infection. During their acute phase, the Long COVID participants had been admitted to various hospitals and centers in Al-Najaf city for treatment of acute COVID-19, namely Al-Sader Medical City of Najaf, Al-Hakeem General Hospital, Al-Zahraa Teaching Hospital for Maternity and Pediatrics, Imam Sajjad

7

Hospital, Hassan Halos Al-Hatmy Hospital for Transmitted Diseases, Middle Euphrates Center Cancer, Al-Najaf Center for Cardiac Surgery and Trans Catheter Therapy. All patients had been diagnosed as moderate to severe acute COVID-19 based on their clinical symptoms and the WHO criteria (World Health Organization 2022) and positive results of reverse transcription real-time polymerase chain reaction (rRT-PCR). Upon recovery all patients showed a negative rRT-PCR test. Three to four months after admission for acute COVID-19 they showed at least two symptoms that were present for at least two months including fatigue, memory or concentration disorders, shortness of breath or difficulty breathing, chest pain, persistant cough, trouble speaking, muscle aches, loss of smell or taste, affective symptoms or fever (World Health Organization 2022). Additionally, we recruited 36 controls from the same catchment area, who were either employees or family or friends of staff members. We also included controls who demonstrated distress or adjustment symptoms because of lockdowns and social isolation to account for their confounding effects that are also evident in Long COVID patients. As such, 1/3 of the controls show HAMD levels between 7 and 12. All controls showed a negative rRT-PCR test and no clinical signs of acute infection including dry cough, sore throat, shortness of breath, loss of appetite, flu-like symptoms, fever, night sweats, and chills. Patients and controls were excluded if they had a lifetime history of psychiatric disorders, including major depression, bipolar disorder, anxiety disorders, schizophrenia, and substance use disorders, except tobacco use disorder (TUD), neuroinflammatory or neurodegenerative disorders including multiple sclerosis, chronic fatigue syndrome (Morris and Maes 2013), Parkinson's and Alzheimer's disease, and stroke, and systemic (auto)immune diseases such as diabetes mellitus, COPD, rheumatoid arthritis and psoriasis, and liver and renal diseases. We also excluded pregnant and lactating women.

8

Before participating in the study, all controls and patients or their parents/legal guardians provided written signed consent. The approval of the study was obtained from the institutional ethics board of the University of Kufa (617/2020). The study was accomplished under Iraqi and foreign ethics and privacy rules according to the guidelines of the World Medical Association Declaration of Helsinki, The Belmont Report, CIOMS Guideline, and International Conference on Harmonization of Good Clinical Practice; our IRB adheres to the International Guideline for Human Research Safety (ICH-GCP).

#### Clinical assessments

A well-trained paramedical professional recorded spO2 with an electronic oximeter provided by Shenzhen Jumper Medical Equipment Co. Ltd. and body temperature as assessed using a digital oral thermometer (sublingual until the beep). In the present study, we extracted both biomarkers from the patient records and used the lowest SpO2 and peak body temperature data that were measured during the acute phase of illness in the analyses. Based on those two assessments we computed a new index which reflects lowered SpO2 and higher temperature as z transformation of body temperature (z T) - z SpO2 (named the "TO2 index"). In all participants we registered the vaccinations they had received, namely AstraZeneca, Pfizer or Sinopharm. A semi-structured interview, conducted by a senior psychiatrist, assessed sociodemographic and clinical data in controls and Long COVID patients three to four months after recovery (mean  $\pm$ SD: 14.68  $\pm$ 5.31 weeks) from acute COVID-19. We assessed the following rating scales: a) depressive symptoms were examined utilizing the 21-item Hamilton Depression Rating Scale (HDRS) score (Hamilton 1960); b) anxiety symptoms were assessed using the Hamilton Anxiety Rating Scale

9

(HAM-A) (Hamilton 1959); and c) and chronic fatigue and fibromyalgia symptoms using the Fibro-Fatigue (FF) 12-item scale (Zachrisson, Regland et al. 2002).

We computed two HAMD subdomain scores: a) pure depressive symptoms (pure HAMD) were calculated as the sum of depressed mood + feelings of guilt + suicidal ideation + loss of interest; and b) physiosomatic HAMD symptoms (Physiosom HAMD) was computed as: anxiety somatic + gastrointestinal + genitourinary + hypochondriasis. Two HAMA subdomain scores were computed: a) key anxiety symptoms (Key HAMA) as anxious mood + tension + fears + anxiety behavior at interview; and b) physiosomatic HAMA symptoms (Physiosom HAMA) as somatic sensory + cardiovascular + gastrointestinal (GIS)+ genitourinary + autonomic symptoms (respiratory symptoms were not included in the sum). We computed one pure physiosom FF subdomain score as muscle pain + muscle tension + fatigue + autonomous symptoms + gastrointestinal symptoms + headache + a flu-like malaise (thus excluding the cognitive and affective symptoms). Moreover, using all relevant HAMD, HAMA, and FF items (z transformed) we calculated z unit based composite scores reflecting autonomic symptoms, sleep disorders, fatigue, gastro-intestinal symptoms, and cognitive symptoms. We calculated the body mass index (BMI) based on the equation dividing body weight in kilograms by height in meter  $^{2}$ . We made the diagnosis of TUD using DSM-5 criteria.

### Data analysis

Differences in continuous variables between groups were checked using analysis of variance (ANOVA). Analysis of contingency tables (the  $\chi$ 2-test) was used to determine the association between nominal variables. Correlations between two variables were assessed using Pearson's product moment correlation coefficients. We employed multivariate and univariate

10

general linear model (GLM) analysis to delineate the associations between study groups (controls versus patients divided into those with low and high TO2 index scores) and rating scale scores while controlling for confounding variables including age, sex, smoking and education. Consequently, we computed the estimated marginal mean values (SE) and conducted protected (the omnibus test is significant) LSD tests to conduct pairwise comparisons among the group means. Multiple comparisons were subjected to false discovery rate (FDR) p-correction (Benjamini and Hochberg 1995). Moreover, we used multiple regression analysis to delineate significant predictors of the rating scale scores while allowing for the effects of confounders. An automated stepwise method was employed with an 0.05 p-value to entry and 0.06 to remove. We computed for each significant explanatory variable the standardized beta coefficients with t statistics and exact p-value, and for the model F statistics and total variance explained  $(R^2)$ . Moreover, we always checked changes in R<sup>2</sup> and collinearity issues using the variance inflation factor and tolerance. The White and modified Breusch-Pagan tests for homoscedasticity were used to check heteroskedasticity and if needed we computed the parameter estimates with robust errors using univariate GLM analysis. The significance was determined at p=0.05, and two-tailed tests were applied. Power analysis showed that using an effect size of 0.23, p=0.05, power=0.8 and three groups with up to 5 covariates in an analysis of variance the sample size should be around 151 subjects. Therefore, we included 156 subjects, namely 36 controls and 120 Long COVID participants.

In accordance with the precision nomothetic approach (Maes 2022) we aimed to construct endophenotype classes of Long COVID patients (using cluster analysis), and new pathway phenotypes (using factor analysis) by combining biomarker and clinical data. Exploratory factor analysis (unweighted least squares extraction, 25 iterations for convergence) was performed, and

11

the Kaiser-Meier-Olkin (KMO) sample adequacy measure was used to assess factorability (sufficient when >0.7). Moreover, when all loadings on the first factor were > 0.6 and the variance explained by the first factor was > 50.0%, and Cronbach alpha performed on the variables was > 0.7, the first PC was regarded as a valid latent construct underpinning the variables. Canonical correlation analysis was used to examine the relationships between two sets of variables, whereby symptoms three to four months after the acute phase were entered as dependent variables and the biomarkers as explanatory variables. We computed the variance explained by the canonical variables of both sets and the variance in the canonical dependent variables set explained by the independent canonical variable set. The canonical components are accepted when the explained variance of both sets is > 0.5 and when all canonical loadings are > 0.5. Two step cluster analysis was performed considering categorical and continuous variables. The cluster solution was considered adequate when the silhouette measure of cohesion and separation was > 0.5. IBM SPSS windows version 28 was used for all statistical analyses.

### Results

### Sociodemographic data

In order to divide the patient sample in two subgroups based on baseline SpO2 and body temperature data we performed two-step cluster analysis with being infected or not as categorical variable and body temperature and SpO2 as continuous variables. This cluster analysis showed three clusters with adequate cluster quality (silhouette measure of cohesion and separation of 0.62) comprising the healthy control sample (n=36), and patients with a low (group 1, n=88) versus very high (group 2, n=32) TO2 index. As such, patients with Long COVID were divided according to measurements during the acute infectious phase. **Table 1** shows the sociodemographic data of

12

these three groups. Group 2 patients (high TO2 index) showed a significant increase in body temperature and decreased spO2 values as compared to group 1 patients (low TO2 index) and controls, while the low TO2 group showed lower SpO2 and higher temperature than controls. No significant differences in these groups were found in sex, TUD, residency, vaccination status, and BMI. The mean age was somewhat higher and education somewhat lower in the high TO2 group as compared with the low TO2 group and controls.

#### Differences in psychiatric rating scales between study groups

The measurements of the total and subdomains scores of the rating scales are displayed in **Table 2.** All total scores, the pure and physiosom HAMD and HAMA and pure FF scores and severity of autonomic and gastro-intestinal symptoms were significantly different between the three study groups and increased from controls  $\rightarrow$  low TO2 group  $\rightarrow$  high TO2 group. Furthermore, there were significant differences in pure HAMA, sleep disorders, fatigue and cognitive impairments between Long COVID patients and controls with a trend toward higher values in the high TO2 group. The intergroup differences remained significant using an FDR of p=0.01. Consequently, we have extracted the first factor from the pure and physiosom HAMD and HAMA and pure FF scores (this first factor explained 66.99% of the variance; KMO=0.877, all loadings on the first factor > 0.724). This factor therefore underpins the different subdomains and was labeled the "physio-affective core" or "physio-affective phenome" of Long COVID. Table 2 shows that this score was significantly different between the three groups.

#### Construction of pathway-phenotypes

13

To construct pathway phenotypes, we employed factor analysis to examine whether latent vectors could be extracted from the SpO2 and body temperature data and the clinical rating scale scores. The results are shown in **Table 3**. The first FA was performed on SpO2, body temperature, TO2 index, and the 5 clinical scale subdomains. This data set showed a sufficient factorability of the correlation matrix and the first factor explained 64.19% of the variance and all factor loadings were > 0.66 with an adequate Cronbach alpha value. This factor, therefore, was dubbed the "TO2-physio-affective" or "TO2PA" pathway phenotype". We could also extract a single latent vector from the SpO2, body temperature, TO2 index, chronic fatigue, GIS, sleep and autonomic symptoms with adequate KMO, Cronbach alpha, and explained variance data.

# Prediction of the clinical rating scales

We performed different multiple regression analyses using the subdomain scores as dependent variables and SpO2, body temperature, vaccination status (entered as dummy variables), age, sex, TUD, and education as explanatory variables (**Table 4**). Regression #1 shows that 38.9% of the variance in pure HAMD scores could be explained by SpO2, education, age (inversely) and body temperature (positively associated). Regression #2 shows that a large portion of the variance (42.7%) in Physiosom HAMD could be explained by SpO2 (inversely) and body temperature (positively) and being vaccinated with AstraZeneca or Pfizer. We found that (regression #3) 33.9% of the variance in pure HAMA was explained by a model involving SpO2 (inegatively), female sex, and vaccination with AstraZeneca. The physiosom HAMA (regression #4) was best predicted by SpO2, body temperature, female sex and vaccination with AstraZeneca or Pfizer. Regression #5 shows that 54.9% of the variance in pure FF scores could be explained by SpO2 (inversely) and peak body temperature (positively). Regression #6 showed that 60.7% of the

14

variance in the physio-affective phenome score was explained by SpO2 (inversely), peak body temperature, female sex and vaccination with AstraZeneca or Pfizer. **Figures 1 and 2** show the partial regression of the physio-affective phenome score on SpO2 and body temperature, respectively. **Figure 3** shows the partial regression of the physio-affective phenome on the TO2 index. Also, in the restricted study sample of patients with Long COVID we found that SpO2 levels were significantly correlated with Pure HAMD (r=0.258, p=0.005, n=120), Physiosom HAMD (r=0420, p<0.001), Pure HAMA (r=0.334, p<0.001), Physiosom HAMA (r=0.559, p<0.001), and Pure FF (r=0.463, p<0.001) scores. These effects remained significant using an FDR of p=0.01. After FDR p correction, no significant correlations were observed between body temperature and the clinical scale scores in the patient sample. In the restricted study sample of COVID patients, we found a significant association between the physio-affective phenome score and the TO2 index (r=0.519, p<0.001, n=118). **Figure 4** shows the partial regression of the physio-affective phenome score affective phenome score and the TO2 index in the restricted study sample of COVID-19 patients only.

### **Results of canonical correlations**

To delineate the associations between SpO2 and body temperature and the different symptom profiles of Long COVID we used canonical correlation analysis with the Long COVID symptom profiles as dependent variables. Table 5 shows that a canonical component extracted from SpO2 and body temperature (explaining 76.6% of the variance) was strongly correlated (explaining 31.0% of the variance) with a factor extracted from HAMD symptoms (explaining 55.1% of the variance), namely depressed mood, insomnia early and middle, GIS and genital symptoms, and hypochondriasis. The same biomarkers explained 31.9% of the variance in a factor extracted from 9 FF symptoms, namely muscle pain and tension, fatigue, irritability, sleep

15

disorders, autonomic and GIS symptoms, headache and a flu-like malaise. Baseline SpO2 and body temperature also explained 34.3% of the variance in a factor extracted from 8 HAMA symptoms, namely anxious mood, tension, insomnia, depressed mood, and sensory, respiratory, genitourinary and autonomic symptoms.

### Discussion

# Clinical aspects of Long COVID

The first major finding of the current study is that increased body temperature and especially decreased levels of SpO<sub>2</sub> in acute COVID-19 predict the onset of mental symptoms, chronic fatigue and physiosomatic (previously named psychosomatic) symptoms that characterize Long COVID. Moreover, based on these two baseline markers of acute COVID-19, we were able to construct a new endophenotype cluster of Long COVID patients who show very low SpO<sub>2</sub>, high body temperature, and increased levels of depressive, anxiety and physiosomatic symptoms, including autonomic and GIS, sleep disorders, fatigue, and cognitive impairments. The estimated number of patients in this new TO2PA (TO2-physio-affective) endophenotype class was around 26.7% of the Long COVID patients. We should stress that the current study did not aim to estimate the prevalence of Long COVID mental symptoms but rather to examine whether baseline biomarkers of infection and immune activation predict mental symptoms and, using the precision nomothetic approach (Maes 2022) to define new endophenotype classes and pathway phenotypes to examine the pathophysiology of Long COVID.

The current results extend those of previous reports, which ubiquitously reported mental and physiosomatic symptoms in Long COVID patients (Huang, Huang et al. 2021, Taquet, Geddes et al. 2021, Titze-de-Almeida, da Cunha et al. 2022). Moreover, recent meta-analyses revealed that

16

the top symptoms of Long COVID were in descending order of importance: fatigue, brain fog, memory disturbances, attention problems, myalgia, anosmia, dysgeusia, and headache (Premraj, Kannapadi et al. 2022). Similar findings were reported in another meta-analysis (Badenoch, Rengasamy et al. 2022) showing that the top most prevalent symptoms were in descending order of importance: sleep disturbances, fatigue, objective cognitive deficits, anxiety and post-traumatic stress. Moreover, these meta-analyses showed that the prevalence of mental symptoms including depression tends to increase over the time from mid to long-term follow up (Premraj, Kannapadi et al. 2022).

Previously, we observed that the acute infectious phase was characterized by intertwined increases in key depression, anxiety and physiosomatic symptoms as assessed with the HAMD, HAMA and FF scales (Al-Jassas, Al-Hakeim et al. 2022). As such, both acute COVID-19 and Long COVID are accompanied by significant intertwined increases in mental and chronic fatigue symptoms. Furthermore, both in the acute infectious phase and Long COVID one single latent trait could be extracted from these mental and physiosomatic symptoms indicating that these symptoms are manifestations of a common core, namely the "physio-affective phenome" of COVID-19 and Long COVID. This indicates that shared pathways may underpin the physio-affective phenome of the acute as well as chronic phases of the illness. Previously, we observed intertwined associations between increased levels of affective and physiosomatic symptoms not only in acute COVID-19 but also in, for example, schizophrenia, rheumatoid arthritis, and major depression (Kanchanatawan, Sriswasdi et al. 2019, Almulla, Al-Hakeim et al. 2020, Maes, Andrés-Rodríguez et al. 2021, Smesam, Qazmooz et al. 2022). Since our previous study (Al-Jassas, Al-Hakeim et al. 2022) and the current study were performed using different study samples, we were unable to examine whether patients with acute physio-affective symptoms present the same symptoms in

17

Long COVID. Nevertheless, since we excluded in both studies patients with primary major depression, anxiety disorders and chronic fatigue syndrome, our findings indicate that SARS-CoV-2 infected patients develop de novo mental symptoms and chronic fatigue during both the acute and the chronic phase of the illness.

# Biomarkers of acute COVID-19 and Long COVID.

The second major finding of this study is that a large part of the severity of the physioaffective core (60.7%) during Long COVID was significantly predicted by SpO2 and body temperature values during the acute phase of the disease. In the latter, we observed that the physioaffective core was strongly associated with a replicable latent vector extracted from SpO2, CCTAs (including crazy patterns, consolidation, ground glass opacities), increased levels of proinflammatory and anti-inflammatory cytokines, and SARS-Cov2 infection (AI-Jassas et al., 2022). These findings indicate that during the acute phase of illness, lowered SpO2 is a manifestation of the infection-immune-inflammatory core which is accompanied by CCTAs. As reviewed in the Introduction, the degree of increased body temperature in the acute phase reflects the severity of inflammation. Moreover, for every 0.5 °C increase in body temperature there is an increase in mortality rate reaching 42.0% in people with a body temperature > 40.0 °C (Tharakan et al., 2020). As such, increased body temperature not only predicts increased mortality rates but also increased severity of the physio-affective phenome.

It should be stressed that during the initial phase of COVID-19 infection, a sickness behavioral complex (SBC) is present, which includes physiosomatic symptoms such as muscle pain and tension, loss of appetite, fatigue, headache and probably also dysgeusia and anosmia (Maes, Tedesco Junior et al. 2022). This SBC protects against severe and critical COVID-19 disease and is partly mediated by NLRP3 (nucleotide-binding domain, leucine-rich repeat and

18

pyrin domain-containing protein 3 inflammasome) gene variants (Maes, Tedesco Junior et al. 2022). Nevertheless, the SBC is a beneficial short-lasting response confined to the acute phase of inflammation and should be discriminated from the affective and chronic fatigue symptoms which accompany the chronic inflammatory phase (Maes, Berk et al. 2012, Morris, Anderson et al. 2013).

Our findings that lowered levels of SpO2 and increased body temperature (and consequently also CCTAs and inflammation) are associated with Long COVID physio-affective symptoms may be explained by several factors. First, both increased body temperature and lowered SpO2 during the acute phase indicate more severe inflammatory responses (Tharakan, Nomoto et al. 2020, Al-Jassas, Al-Hakeim et al. 2022), which could further develop into chronic inflammatory responses (Maes, Berk et al. 2012). Signs of activated immune-inflammatory pathways were observed in Long COVID including increased levels of interleukin (IL)-2, IL-1 $\beta$ , IL-6, IL-17A, IL-12p70, interferon (IFN)- $\gamma$ , tumor necrosis factor (TNF)- $\alpha$  and macrophage inflammatory protein1 $\beta$ , and increased levels of acute phase reactants such as C-reactive protein and ferritin (Breton, Mendoza et al. 2020, Mazza, De Lorenzo et al. 2020, Santis, Pérez-Camacho et al. 2020, García-Abellán, Padilla et al. 2021, Ong, Fong et al. 2021, Sonnweber, Sahanic et al. 2021, Ceban, Ling et al. 2022). Activation of immune-inflammatory pathways may explain the onset of affective and physiosomatic symptoms as well as chronic fatigue syndrome (Maes, Berk et al. 2012, Morris, Anderson et al. 2013).

Second, lowered SpO2 itself may cause fatigue and depressive symptoms (Pan, Zhao et al. 2015, Zhao, Yang et al. 2017) and is implicated in cognitive impairments (Wang, Cui et al. 2022), autonomic symptoms (Chen, Chen et al. 2006) and insomnia (Johansson, Svensson et al. 2015). Hypoxia-inducible factors (HIFs) are key regulators of oxygen homeostasis (Yoon, Pastore et al. 2006) which are induced in response to hypoxia thereby promoting angiogenesis (Carmeliet, Dor

19

et al. 1998) and anaerobic metabolism (Carmeliet, Dor et al. 1998, Vaupel 2004), while lowering mitochondrial oxygen via activating pyruvate kinase I enzyme and inhibiting the citric acid cycle (Ziello, Jovin et al. 2007, Morris, Maes et al. 2019). Importantly, HIF1A is part of the immune protein-protein interaction network of affective disorders (Maes, Rachayon et al. 2022) and inflammatory responses in general (Cramer, Yamanishi et al. 2003, Oda, Hirota et al. 2006, Imtiyaz and Simon 2010). Hence, hypoxia and inflammation in acute COVID-19 may be accompanied by overexpression of HIFs which may further fuel the immune-inflammatory disorders leading to Long COVID. Moreover, hypoxia may cause increases in reactive oxygen and nitrogen species (Solaini, Baracca et al. 2010), leading to oxidative damage, which is implicated in the pathophysiology of depression, fatigue and anxiety (Maes, Kubera et al. 2011, Morris and Maes 2014). Furthermore, different areas of the brain, mainly the structures that take part in affective disorders, namely the amygdala, hippocampus, anterior cingulate cortex, and prefrontal cortex (Aryutova and Stoyanov 2021) were found to be influenced by hypoxia (Shankaranarayana Rao, Raju et al. 1999, Alchanatis, Zias et al. 2005).

Third, decreased SpO2 in acute COVID-19 is attributed to lung inflammation, bronchitis, pneumonia and lung fibrosis as indicated by the presence of CCTAs (Sadhukhan, Ugurlu et al. 2020, Solomon, Heyman et al. 2021, Al-Jassas, Al-Hakeim et al. 2022). Up to fifty percent of the post-COVID-19 patients may show some signs of lung fibrosis (Nabahati, Ebrahimpour et al. 2021) and 2-6% of Long COVID patients who experienced moderate COVID-19 illness develop lung fibrosis (Bazdyrev, Rusina et al. 2021). In addition, a significant cohort of recovered patients show more persistent lung inflammation which may cause physiological and functional changes (Myall, Mukherjee et al. 2021) and even CCTAs were reported in some of Long COVID patients (Solomon, Heyman et al. 2021, Vijayakumar, Tonkin et al. 2021). All in all, increased lung

20

inflammation and fibrosis in the post-infectious phase may further contribute to lowered SpO2 and immune-inflammatory responses and thus the physio-affective phenome of Long COVID. A fourth possibility is that some COVID vaccines contribute to the physio-somatic phenome of Long COVID. In this regard we observed that AstraZeneca and Pfizer vaccinations aggravated the physiosomatic phenome, whereas Sinopharm had no such effect.

# Limitations

Some limitations and strengths should be considered while interpreting the current results. First, the paper would have been more interesting if we had measured HIFs and the tryptophan catabolite (TRYCAT) pathway in the acute and chronic phase of the disease. Indeed, a recent metaanalysis showed that neurotoxic TRYCATs are significantly increased in acute COVID-19, while TRYCATs are known to be associated with the onset of affective, physiosomatic and cognitive symptoms (Maes, Leonard et al. 2011, Kanchanatawan, Sirivichayakul et al. 2018, Almulla and Maes 2022, Almulla, Supasitthumrong et al. 2022). Second, although we conducted a case-control study, we also measured body temperature and SpO2 in the acute phase of illness using a retrospective cohort study design which allows to examine causal associations.

## Conclusions

In people with Long COVID, low SpO2 and higher peak body temperature during the acute phase predict the affective and physiosomatic symptoms, chronic fatigue, sleep disturbances, cognitive impairments, and GIS and autonomic symptoms of Long COVID. As such, lowered SpO2 and higher body temperature and the associated CCTAs and immune-inflammatory

21

responses during the acute phase are new drug targets to prevent the Long COVID-associated physio-affective phenome.

# Acknowledgements

The authors thank the staff of Al-Sader Medical City of Najaf, Al-Hakeem General Hospital, Al-Zahraa Teaching Hospital for Maternity and Pediatrics, Imam Sajjad Hospital, Hassan Halos Al-Hatmy Hospital for Transmitted Diseases, Middle Euphrates Center Cancer, Al-Najaf Center for Cardiac Surgery and Trans Catheter Therapy for their efforts in the collection of data.

### Ethical approval and consent to participate

All the controls and patients or their parents/legal guardians provided written signed consent. The approval of the study was obtained from the institutional ethics board of the University of Kufa (617/2020). The study was conducted according to Iraqi and foreign ethics and privacy laws in accordance with the guidelines of the World Medical Association Declaration of Helsinki, The Belmont Report, CIOMS Guideline, and International Conference on Harmonization of Good Clinical Practice; our IRB adheres to the International Guideline for Human Research Safety (ICH-GCP).

#### **Declaration of interest**

The authors declare no financial conflict of interests.

### Funding

22

There is no specific funding for this study

## **Author's contributions**

The preparation of the manuscript was made with participation of all authors and they approved the final version.

# References

Ahmed, H., K. Patel, D. C. Greenwood, S. Halpin, P. Lewthwaite, A. Salawu, L. Eyre, A. Breen, R. O'Connor, A. Jones and M. Sivan (2020). "Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis." <u>J Rehabil Med</u> **52**(5): jrm00063.

Al-Jassas, H. K., H. K. Al-Hakeim and M. Maes (2022). "Intersections between pneumonia, lowered oxygen saturation percentage and immune activation mediate depression, anxiety, and chronic fatigue syndrome-like symptoms due to COVID-19: A nomothetic network approach." Journal of Affective Disorders **297**: 233-245.

Alchanatis, M., N. Zias, N. Deligiorgis, A. Amfilochiou, G. Dionellis and D. Orphanidou (2005). "Sleep apnea-related cognitive deficits and intelligence: an implication of cognitive reserve theory." Journal of Sleep Research 14(1): 69-75.

Almulla, A. F., H. K. Al-Hakeim, M. S. Abed, A. F. Carvalho and M. Maes (2020). "Chronic fatigue and fibromyalgia symptoms are key components of deficit schizophrenia and are strongly associated with activated immune-inflammatory pathways." <u>Schizophrenia Research</u> **222**: 342-353.

23

Almulla, A. F. and M. Maes (2022). "The tryptophan catabolite or kynurenine pathway's role in major depression." Preprints **2022010134**.

Almulla, A. F., T. Supasitthumrong, C. Tunvirachaisakul, A. A. A. Algon, H. K. Al-Hakeim and

M. Maes (2022). "The tryptophan catabolite or kynurenine pathway in COVID-19 and critical

COVID-19: a systematic review and meta-analysis." medRxiv: 2022.2002.2001.22270268.

Aryutova, K. and D. Stoyanov (2021). "Pharmaco-Magnetic Resonance as a Tool for Monitoring the Medication-Related Effects in the Brain May Provide Potential Biomarkers for Psychotic Disorders." <u>International Journal of Molecular Sciences</u> **22**(17).

Badenoch, J. B., E. R. Rengasamy, C. Watson, K. Jansen, S. Chakraborty, R. D. Sundaram, D.Hafeez, E. Burchill, A. Saini, L. Thomas, B. Cross, C. K. Hunt, I. Conti, S. Ralovska, Z. Hussain,

M. Butler, T. A. Pollak, I. Koychev, B. D. Michael, H. Holling, T. R. Nicholson, J. P. Rogers and

A. G. Rooney (2022). "Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis." <u>Brain Commun</u> **4**(1): fcab297.

Bazdyrev, E., P. Rusina, M. Panova, F. Novikov, I. Grishagin and V. Nebolsin (2021). "Lung Fibrosis after COVID-19: Treatment Prospects." Pharmaceuticals (Basel) **14**(8).

Benjamini, Y. and Y. Hochberg (1995). "Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing." Journal of the Royal Statistical Society: Series B (Methodological) **57**(1): 289-300.

Boldrini, M., P. D. Canoll and R. S. Klein (2021). "How COVID-19 Affects the Brain." JAMA Psychiatry **78**(6): 682-683.

Breton, G., P. Mendoza, T. Hagglof, T. Y. Oliveira, D. Schaefer-Babajew, C. Gaebler, M. Turroja,
A. Hurley, M. Caskey and M. C. Nussenzweig (2020). "Persistent Cellular Immunity to SARS-CoV-2 Infection." bioRxiv : the preprint server for biology: 2020.2012.2008.416636.

24

Calabrese, L. H. (2020). "Cytokine storm and the prospects for immunotherapy with COVID-19." Cleve Clin J Med **87**(7): 389-393.

Carmeliet, P., Y. Dor, J. M. Herbert, D. Fukumura, K. Brusselmans, M. Dewerchin, M. Neeman, F. Bono, R. Abramovitch, P. Maxwell, C. J. Koch, P. Ratcliffe, L. Moons, R. K. Jain, D. Collen and E. Keshert (1998). "Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis." <u>Nature</u> **394**(6692): 485-490.

Ceban, F., S. Ling, L. M. W. Lui, Y. Lee, H. Gill, K. M. Teopiz, N. B. Rodrigues, M. Subramaniapillai, J. D. Di Vincenzo, B. Cao, K. Lin, R. B. Mansur, R. C. Ho, J. D. Rosenblat, K. W. Miskowiak, M. Vinberg, V. Maletic and R. S. McIntyre (2022). "Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis." <u>Brain Behav Immun</u> 101: 93-135.

Chen, W. L., G. Y. Chen and C. D. Kuo (2006). "Hypoxemia and autonomic nervous dysfunction in patients with chronic obstructive pulmonary disease." <u>Respir Med</u> **100**(9): 1547-1553.

Cramer, T., Y. Yamanishi, B. E. Clausen, I. Förster, R. Pawlinski, N. Mackman, V. H. Haase, R. Jaenisch, M. Corr, V. Nizet, G. S. Firestein, H. P. Gerber, N. Ferrara and R. S. Johnson (2003). "HIF-1alpha is essential for myeloid cell-mediated inflammation." Cell **112**(5): 645-657.

Cvejic, E., H. Li, I. B. Hickie, D. Wakefield, A. R. Lloyd and U. Vollmer-Conna (2019). "Contribution of individual psychological and psychosocial factors to symptom severity and timeto-recovery after naturally-occurring acute infective illness: The Dubbo Infection Outcomes Study (DIOS)." <u>Brain Behav Immun</u> **82**: 76-83.

Davido, B., S. Seang, R. Tubiana and P. de Truchis (2020). "Post–COVID-19 chronic symptoms: a postinfectious entity?" <u>Clinical Microbiology and Infection</u> **26**(11): 1448-1449.

25

Deng, J., F. Zhou, W. Hou, Z. Silver, C. Y. Wong, O. Chang, E. Huang and Q. K. Zuo (2021). "The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a metaanalysis." Annals of the New York Academy of Sciences **1486**(1): 90-111.

García-Abellán, J., S. Padilla, M. Fernández-González, J. A. García, V. Agulló, M. Andreo, S. Ruiz, A. Galiana, F. Gutiérrez and M. Masiá (2021). "Long-term clinical, virological and immunological outcomes in patients hospitalized for COVID-19: antibody response predicts long COVID." medRxiv: 2021.2003.2008.21253124.

Hamilton, m. (1959). "The assessment of anxiety states by rating "<u>British Journal of Medical</u> <u>Psychology</u> **32**(1): 50-55.

Hamilton, M. (1960). "A rating scale for depression " Journal of Neurology, Neurosurgery & amp; Psychiatry **23**(1): 56.

Huang, C., L. Huang, Y. Wang, X. Li, L. Ren, X. Gu, L. Kang, L. Guo, M. Liu, X. Zhou, J. Luo,

Z. Huang, S. Tu, Y. Zhao, L. Chen, D. Xu, Y. Li, C. Li, L. Peng, Y. Li, W. Xie, D. Cui, L. Shang,
G. Fan, J. Xu, G. Wang, Y. Wang, J. Zhong, C. Wang, J. Wang, D. Zhang and B. Cao (2021). "6month consequences of COVID-19 in patients discharged from hospital: a cohort study." <u>The</u>
<u>Lancet</u> 397(10270): 220-232.

Huang, Y., M. D. Pinto, J. L. Borelli, M. A. Mehrabadi, H. Abrihim, N. Dutt, N. Lambert, E. L. Nurmi, R. Chakraborty, A. M. Rahmani and C. A. Downs (2021). "COVID Symptoms, Symptom Clusters, and Predictors for Becoming a Long-Hauler: Looking for Clarity in the Haze of the Pandemic." <u>medRxiv</u>.

Imtiyaz, H. Z. and M. C. Simon (2010). "Hypoxia-inducible factors as essential regulators of inflammation." <u>Current topics in microbiology and immunology</u> **345**: 105-120.

26

Jackson, M. L. and D. Bruck (2012). "Sleep abnormalities in chronic fatigue syndrome/myalgic encephalomyelitis: a review." J Clin Sleep Med **8**(6): 719-728.

Johansson, P., E. Svensson, U. Alehagen, T. Jaarsma and A. Broström (2015). "The contribution of hypoxia to the association between sleep apnoea, insomnia, and cardiovascular mortality in community-dwelling elderly with and without cardiovascular disease." <u>Eur J Cardiovasc Nurs</u> **14**(3): 222-231.

Kanchanatawan, B., S. Sirivichayakul, K. Ruxrungtham, A. F. Carvalho, M. Geffard, H. Ormstad,
G. Anderson and M. Maes (2018). "Deficit, but Not Nondeficit, Schizophrenia Is Characterized
by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly
Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid."
<u>Mol Neurobiol</u> 55(2): 1524-1536.

Kanchanatawan, B., S. Sriswasdi and M. Maes (2019). "Supervised machine learning to decipher the complex associations between neuro-immune biomarkers and quality of life in schizophrenia." <u>Metabolic Brain Disease</u> **34**(1): 267-282.

Lam, M. H., Y. K. Wing, M. W. Yu, C. M. Leung, R. C. Ma, A. P. Kong, W. Y. So, S. Y. Fong and S. P. Lam (2009). "Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up." <u>Arch Intern Med</u> **169**(22): 2142-2147.

Lee, S. H., H.-S. Shin, H. Y. Park, J. L. Kim, J. J. Lee, H. Lee, S.-D. Won and W. Han (2019). "Depression as a Mediator of Chronic Fatigue and Post-Traumatic Stress Symptoms in Middle East Respiratory Syndrome Survivors." <u>Psychiatry investigation</u> **16**(1): 59-64.

Lopez-Leon, S., T. Wegman-Ostrosky, C. Perelman, R. Sepulveda, P. A. Rebolledo, A. Cuapio and S. Villapol (2021). "More than 50 long-term effects of COVID-19: a systematic review and meta-analysis." Scientific Reports **11**(1): 16144.

27

Maes, M. (2022). "Precision Nomothetic Medicine in Depression Research: A New Depression Model, and New Endophenotype Classes and Pathway Phenotypes, and A Digital Self." <u>J Pers</u> <u>Med</u> **12**(3).

Maes, M., L. Andrés-Rodríguez, A. Vojdani, S. Sirivichayakul, D. S. Barbosa and B. Kanchanatawan (2021). "In schizophrenia, chronic fatigue syndrome- and fibromyalgia-like symptoms are driven by breakdown of the paracellular pathway with increased zonulin and immune activation-associated neurotoxicity." <u>medRxiv</u>: 2021.2005.2009.21256897.

Maes, M., M. Berk, L. Goehler, C. Song, G. Anderson, P. Gałecki and B. Leonard (2012). "Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways." BMC Medicine **10**(1): 66.

Maes, M., M. Kubera, E. Obuchowiczwa, L. Goehler and J. Brzeszcz (2011). "Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways." <u>Neuro Endocrinol Lett</u> **32**(1): 7-24.

Maes, M., B. E. Leonard, A. M. Myint, M. Kubera and R. Verkerk (2011). "The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression." <u>Prog</u> <u>Neuropsychopharmacol Biol Psychiatry</u> **35**(3): 702-721.

Maes, M., M. Rachayon, K. Jirakran, P. Sodsai, S. Klinchanhom, P. Gałecki, A. Sughondhabirom and A. Basta-Kaim (2022). "The Immune Profile of Major Dysmood Disorder: Proof of Concept and Mechanism Using the Precision Nomothetic Psychiatry Approach." <u>Cells</u> **11**(7).

Maes, M., W. L. D. Tedesco Junior, M. A. B. Lozovoy, M. T. E. Mori, T. Danelli, E. R. D. d. Almeida, A. M. Tejo, Z. N. Tano, E. M. V. Reiche and A. N. C. Simão (2022). "In COVID-19,

NLRP3 inflammasome genetic variants are associated with critical disease and these effects are partly mediated by the sickness symptom complex: a nomothetic network approach." <u>Molecular</u> <u>Psychiatry</u>.

Mazza, M. G., R. De Lorenzo, C. Conte, S. Poletti, B. Vai, I. Bollettini, E. M. T. Melloni, R. Furlan, F. Ciceri, P. Rovere-Querini and F. Benedetti (2020). "Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors." <u>Brain, Behavior, and Immunity</u> **89**: 594-600.

Mehta, P., D. F. McAuley, M. Brown, E. Sanchez, R. S. Tattersall and J. J. Manson (2020). "COVID-19: consider cytokine storm syndromes and immunosuppression." <u>The Lancet</u> **395**(10229): 1033-1034.

Moldofsky, H. and J. Patcai (2011). "Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study." <u>BMC</u> <u>Neurol</u> **11**: 37.

Morris, G., G. Anderson, P. Galecki, M. Berk and M. Maes (2013). "A narrative review on the similarities and dissimilarities between myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and sickness behavior." <u>BMC Med</u> **11**: 64.

Morris, G. and M. Maes (2013). "Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics." <u>BMC Medicine</u> **11**(1): 205.

Morris, G. and M. Maes (2014). "Oxidative and Nitrosative Stress and Immune-Inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS)." Current neuropharmacology **12**(2): 168-185.

29

Morris, G., M. Maes, M. Berk and B. K. Puri (2019). "Myalgic encephalomyelitis or chronic fatigue syndrome: how could the illness develop?" Metab Brain Dis **34**(2): 385-415.

Myall, K. J., B. Mukherjee, A. M. Castanheira, J. L. Lam, G. Benedetti, S. M. Mak, R. Preston,
M. Thillai, A. Dewar, P. L. Molyneaux and A. G. West (2021). "Persistent Post-COVID-19
Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment." <u>Ann Am Thorac</u> Soc 18(5): 799-806.

Nabahati, M., S. Ebrahimpour, R. Khaleghnejad Tabari and R. Mehraeen (2021). "Post-COVID-19 pulmonary fibrosis and its predictive factors: a prospective study." <u>Egyptian Journal of</u> <u>Radiology and Nuclear Medicine</u> **52**(1): 248.

Nalbandian, A., K. Sehgal, A. Gupta, M. V. Madhavan, C. McGroder, J. S. Stevens, J. R. Cook,
A. S. Nordvig, D. Shalev, T. S. Sehrawat, N. Ahluwalia, B. Bikdeli, D. Dietz, C. Der-Nigoghossian, N. Liyanage-Don, G. F. Rosner, E. J. Bernstein, S. Mohan, A. A. Beckley, D. S.
Seres, T. K. Choueiri, N. Uriel, J. C. Ausiello, D. Accili, D. E. Freedberg, M. Baldwin, A.
Schwartz, D. Brodie, C. K. Garcia, M. S. V. Elkind, J. M. Connors, J. P. Bilezikian, D. W. Landry
and E. Y. Wan (2021). "Post-acute COVID-19 syndrome." <u>Nat Med</u> 27(4): 601-615.

Nelson, M. J., J. S. Bahl, J. D. Buckley, R. L. Thomson and K. Davison (2019). "Evidence of altered cardiac autonomic regulation in myalgic encephalomyelitis/chronic fatigue syndrome: A systematic review and meta-analysis." <u>Medicine (Baltimore)</u> **98**(43): e17600.

Oda, T., K. Hirota, K. Nishi, S. Takabuchi, S. Oda, H. Yamada, T. Arai, K. Fukuda, T. Kita, T. Adachi, G. L. Semenza and R. Nohara (2006). "Activation of hypoxia-inducible factor 1 during macrophage differentiation." <u>Am J Physiol Cell Physiol</u> **291**(1): C104-113.

Ong, S. W. X., S. W. Fong, B. E. Young, Y. H. Chan, B. Lee, S. N. Amrun, R. S. Chee, N. K. Yeo, P. Tambyah, S. Pada, S. Y. Tan, Y. Ding, L. Renia, Y. S. Leo, L. F. P. Ng and D. C. Lye (2021).

30

"Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients." <u>Open Forum Infect Dis</u> **8**(6): ofab156.

Pan, J., P. Zhao, H. Cai, L. Su, K. Wood, F. D. Shi and Y. Fu (2015). "Hypoxemia, Sleep Disturbances, and Depression Correlated with Fatigue in Neuromyelitis Optica Spectrum Disorder." CNS Neurosci Ther **21**(7): 599-606.

Papadopoulos, A. S. and A. J. Cleare (2011). "Hypothalamic-pituitary-adrenal axis dysfunction in chronic fatigue syndrome." <u>Nat Rev Endocrinol</u> **8**(1): 22-32.

Pelaia, C., C. Tinello, A. Vatrella, G. De Sarro and G. Pelaia (2020). "Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications." Therapeutic Advances in Respiratory Disease **14**: 1753466620933508.

Phillips, S. and M. A. Williams (2021). "Confronting Our Next National Health Disaster - Long-Haul Covid." <u>N Engl J Med</u> **385**(7): 577-579.

Piraino, B., U. Vollmer-Conna and A. R. Lloyd (2012). "Genetic associations of fatigue and other symptom domains of the acute sickness response to infection." <u>Brain Behav Immun</u> **26**(4): 552-558.

Premraj, L., N. V. Kannapadi, J. Briggs, S. M. Seal, D. Battaglini, J. Fanning, J. Suen, C. Robba,
J. Fraser and S. M. Cho (2022). "Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis." J Neurol Sci 434: 120162.

Proal, A. D. and M. B. VanElzakker (2021). "Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms." <u>Frontiers in Microbiology</u> **12**.

Renaud-Charest, O., L. M. W. Lui, S. Eskander, F. Ceban, R. Ho, J. D. Di Vincenzo, J. D. Rosenblat, Y. Lee, M. Subramaniapillai and R. S. McIntyre (2021). "Onset and frequency of

depression in post-COVID-19 syndrome: A systematic review." Journal of psychiatric research **144**: 129-137.

Sadhukhan, P., M. T. Ugurlu and M. O. Hoque (2020). "Effect of COVID-19 on Lungs: Focusing on Prospective Malignant Phenotypes." Cancers (Basel) **12**(12).

Sandler, C. X., V. B. B. Wyller, R. Moss-Morris, D. Buchwald, E. Crawley, J. Hautvast, B. Z.

Katz, H. Knoop, P. Little, R. Taylor, K.-A. Wensaas and A. R. Lloyd (2021). "Long COVID and Post-infective Fatigue Syndrome: A Review." <u>Open forum infectious diseases</u> **8**(10): ofab440-ofab440.

Santis, L. V.-D., I. Pérez-Camacho, B. Sobrino, G. E. González, J. D. Ruíz-Mesa, A. Plata, I. Márquez-Gómez, M. Delgado-Fernández, M. Castaño, F. Oñate, F. Orihuela, B. Palop and J. María Reguera (2020). "Clinical and immunoserological status 12 weeks after infection with COVID-19: prospective observational study." <u>medRxiv</u>: 2020.2010.2006.20206060.

Shankaranarayana Rao, B. S., T. R. Raju and B. L. Meti (1999). "Increased numerical density of synapses in CA3 region of hippocampus and molecular layer of motor cortex after self-stimulation rewarding experience." <u>Neuroscience</u> **91**(3): 799-803.

Smesam, H. N., H. A. Qazmooz, S. Q. Khayoon, A. F. Almulla, H. K. Al-Hakeim and M. Maes (2022). "Pathway Phenotypes Underpinning Depression, Anxiety, and Chronic Fatigue Symptoms Due to Acute Rheumatoid Arthritis: A Precision Nomothetic Psychiatry Analysis." Journal of <u>Personalized Medicine</u> **12**(3): 476.

Solaini, G., A. Baracca, G. Lenaz and G. Sgarbi (2010). "Hypoxia and mitochondrial oxidative metabolism." <u>Biochimica et Biophysica Acta (BBA) - Bioenergetics</u> **1797**(6): 1171-1177.

Solomon, J. J., B. Heyman, J. P. Ko, R. Condos and D. A. Lynch (2021). "CT of Post-Acute Lung Complications of COVID-19." <u>Radiology</u> **301**(2): E383-E395.

32

Solomon, T. (2021). "Neurological infection with SARS-CoV-2 — the story so far." <u>Nature</u> Reviews Neurology **17**(2): 65-66.

Song, E., C. Zhang, B. Israelow, A. Lu-Culligan, A. V. Prado, S. Skriabine, P. Lu, O.-E. Weizman,

F. Liu, Y. Dai, K. Szigeti-Buck, Y. Yasumoto, G. Wang, C. Castaldi, J. Heltke, E. Ng, J. Wheeler,

M. M. Alfajaro, E. Levavasseur, B. Fontes, N. G. Ravindra, D. Van Dijk, S. Mane, M. Gunel, A.

Ring, S. A. J. Kazmi, K. Zhang, C. B. Wilen, T. L. Horvath, I. Plu, S. Haik, J.-L. Thomas, A.

Louvi, S. F. Farhadian, A. Huttner, D. Seilhean, N. Renier, K. Bilguvar and A. Iwasaki (2021).

"Neuroinvasion of SARS-CoV-2 in human and mouse brainNeuroinvasion of SARS-CoV-2 in

humans and mice." Journal of Experimental Medicine 218(3).

Sonnweber, T., S. Sahanic, A. Pizzini, A. Luger, C. Schwabl, B. Sonnweber, K. Kurz, S. Koppelstätter, D. Haschka, V. Petzer, A. Boehm, M. Aichner, P. Tymoszuk, D. Lener, M. Theurl, A. Lorsbach-Köhler, A. Tancevski, A. Schapfl, M. Schaber, R. Hilbe, M. Nairz, B. Puchner, D. Hüttenberger, C. Tschurtschenthaler, M. Aßhoff, A. Peer, F. Hartig, R. Bellmann, M. Joannidis, C. Gollmann-Tepeköylü, J. Holfeld, G. Feuchtner, A. Egger, G. Hoermann, A. Schroll, G. Fritsche, S. Wildner, R. Bellmann-Weiler, R. Kirchmair, R. Helbok, H. Prosch, D. Rieder, Z. Trajanoski, F. Kronenberg, E. Wöll, G. Weiss, G. Widmann, J. Löffler-Ragg and I. Tancevski (2021).
"Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial." <u>The European respiratory journal</u> 57(4): 2003481.

Taquet, M., J. R. Geddes, M. Husain, S. Luciano and P. J. Harrison (2021). "6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records." <u>The Lancet Psychiatry</u> **8**(5): 416-427.

Tharakan, S., K. Nomoto, S. Miyashita and K. Ishikawa (2020). "Body temperature correlates with mortality in COVID-19 patients." <u>Critical Care</u> **24**(1): 298.

33

Theorell, T., V. Blomkvist, G. Lindh and B. Evengård (1999). "Critical life events, infections, and symptoms during the year preceding chronic fatigue syndrome (CFS): an examination of CFS patients and subjects with a nonspecific life crisis." <u>Psychosom Med</u> **61**(3): 304-310.

Titze-de-Almeida, R., T. R. da Cunha, L. D. Dos Santos Silva, C. S. Ferreira, C. P. Silva, A. P. Ribeiro, A. de Castro Moreira Santos Junior, P. R. de Paula Brandao, A. P. B. Silva, M. C. O. da Rocha, M. E. Xavier, S. S. Titze-de-Almeida, H. E. Shimizu and R. N. Delgado-Rodrigues (2022). "Persistent, new-onset symptoms and mental health complaints in Long COVID in a Brazilian cohort of non-hospitalized patients." <u>BMC Infect Dis</u> **22**(1): 133.

Vaupel, P. (2004). "The role of hypoxia-induced factors in tumor progression." <u>Oncologist</u> **9 Suppl 5**: 10-17.

Vijayakumar, B., J. Tonkin, A. Devaraj, K. E. J. Philip, C. M. Orton, S. R. Desai and P. L. Shah (2021). "CT Lung Abnormalities after COVID-19 at 3 Months and 1 Year after Hospital Discharge." Radiology **0**(0): 211746.

Wang, X., L. Cui and X. Ji (2022). "Cognitive impairment caused by hypoxia: from clinical evidences to molecular mechanisms." <u>Metabolic Brain Disease</u> **37**(1): 51-66.

World Health Organization, W. (2022). "Coronavirus disease (COVID-19)." 2022, from https://www.who.int/health-topics/coronavirus#tab=tab\_1.

World Health Organization, W. (2022). "Coronavirus disease (COVID-19): Post COVID-19 condition." Retrieved 37-March, 2022, from <u>https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition.</u>

Yoon, D., Y. D. Pastore, V. Divoky, E. Liu, A. E. Mlodnicka, K. Rainey, P. Ponka, G. L. Semenza, A. Schumacher and J. T. Prchal (2006). "Hypoxia-inducible factor-1 deficiency results in

dysregulated erythropoiesis signaling and iron homeostasis in mouse development." <u>J Biol Chem</u> **281**(35): 25703-25711.

Zachrisson, O., B. Regland, M. Jahreskog, M. Kron and C. G. Gottfries (2002). "A rating scale for

fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale)." Journal of Psychosomatic

<u>Research</u> 52(6): 501-509.

Zhao, F., J. Yang and R. Cui (2017). "Effect of Hypoxic Injury in Mood Disorder." <u>Neural</u> plasticity **2017**: 6986983-6986983.

Ziello, J. E., I. S. Jovin and Y. Huang (2007). "Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia." <u>The Yale</u> journal of biology and medicine **80**(2): 51-60.

Variables	<b>CP</b> ( <b>n</b> =36) <sup>A</sup>	LC and lower TO2 (n=88) <sup>B</sup>	LC and high TO2 (n=32) <sup>C</sup>	F/KWT/X <sup>2</sup>	df	р
Age (years)	30.9 (8.3) <sup>C</sup>	29.7 (7.3) <sup>C</sup>	35.6 (9.6) <sup>A,B</sup>	6.22	2/153	0.003
Sex (M/F)	30/6	59/29	26/6	4.67	2	0.096
Marital state (Ma/S)	14/22	48/40	23/9	7.43	2	0.024
Smoking (Y/N)	16/20	28/60	9/23	2.43	2	0.297
Residency (U/R)	29/7	72/16	29/3	1.57	2	0.456
Vaccination (A/PF/S)	11/14/11	37/34/17	6/17/9	6.86	4	0.145
BMI (kg/m <sup>2</sup> )	26.3 (3.6)	26.3 (5.1)	26.1 (5.4)	0.03	2/148	0.975
Education (years)	15.8 (1.2) <sup>C</sup>	15.8 (1.7) <sup>C</sup>	14.9 (1.3) <sup>A,B</sup>	3.61	2/153	0.029
Maximal BT (°C)	36.5 (0.1) <sup>B,C</sup>	38.7 (0.5) <sup>A,C</sup>	40.1 (0.7) <sup>A,B</sup>	KWT	-	< 0.0001
Lowest SpO <sub>2</sub> (%)	96.58 (1.48) <sup>B,C</sup>	91.50 (3.06) <sup>A,C</sup>	85.84 (6.30) <sup>A,B</sup>	KWT	-	< 0.0001
TO2 index (z scores)	-1.338 (0.179) <sup>B,C</sup>	0.155 (0.398) <sup>A,C</sup>	1.345 (0.659) <sup>A,B</sup>	KWT	-	< 0.0001

**Table 1**. Socio-demographic data, body temperature (BT) and oxygen saturation (SpO2) in control participants (CP) and Long COVID (LC) patients divided according to their TO2 index.

Results are shown as mean (SD): F: results of analysis of variance; KWT: Kruskal Wallis test; X<sup>2</sup>: analysis of contingency tables. M: Male, F: Female, Ma: Married, S: Single, U: Urban, R: Rural, BMI: Body Mass Index, TO2 index: computed as z BT – z SpO2. A: AstraZeneca, Pf: Pfizer, S: Sinopharm

A,B,C: Results of pairwise comparisons among group means

Variables	CP (n=36) <sup>A</sup>	LC and lower TO2 (n=88) <sup>B</sup>	LC and high TO2 (n=32) <sup>C</sup>	F	Df	р
Total HAMD	5.09 (0.86) <sup>B,C</sup>	16.57 (0.56) <sup>A,C</sup>	19.53 (0.96) <sup>A,B</sup>	70.02	2/149	< 0.0001
Total HAMA	7.58 (1.29) <sup>B,C</sup>	19.00 (0.835) <sup>A,C</sup>	24.13 (1.43) <sup>A,B</sup>	42.34	2/149	<0.0001
Total FF	6.96 (1.72) <sup>в,с</sup>	25.26 (1.10) <sup>A,C</sup>	30.34 (1.91) <sup>A,B</sup>	52.76	2/149	< 0.0001
Pure HAMD	1.64 (0.30) <sup>B,C</sup>	4.70 (0.20) <sup>A,C</sup>	5.56 (0.34) <sup>A,B</sup>	47.22	2/149	< 0.0001
Psysiosom HAMD	1.62 (0.35) <sup>B,C</sup>	4.68 (0.23) <sup>A,C</sup>	5.96 (0.39) <sup>A,B</sup>	39.91	2/149	<0.0001
Pure HAMA	1.64 (0.33) <sup>B,C</sup>	3.52 (0.21) <sup>A</sup>	4.12 (0.36) <sup>A</sup>	16.03	2/149	<0.0001
Physiosom HAMA	3.11 (0.63) в,с	8.55 (0.41) <sup>A,C</sup>	11.85 (0.70) <sup>A,B</sup>	46.06	2/149	< 0.0001
Pure FF	4.47 (1.06) <sup>B,C</sup>	16.93 (0.69) <sup>A,C</sup>	20.23 (1.18) <sup>A,B</sup>	62.97	2/149	<0.0001
Physio-affective phenome (z score)	-1.175 (0.124) <sup>B,C</sup>	0.202 (0.080) <sup>A,C</sup>	0.766 (0.137) <sup>A,B</sup>	64.07	2/149	< 0.001
Autonomic symptoms (z score)	-1.172 (0.120) <sup>B,C</sup>	0.180 (0.078) <sup>A,C</sup>	0.824 (0.134) <sup>A,B</sup>	69.64	2/149	< 0.0001
Sleep disorders (z score)	-0.928 (0.144) <sup>B,C</sup>	0.224 (0.093) <sup>A</sup>	0.428 (0.160) <sup>A</sup>	27.45	2/149	<0.0001
Fatigue (z score)	-1.042 (0.136) <sup>B,C</sup>	0.230 (0.089) <sup>A</sup>	0.539 (0.152) <sup>A</sup>	39.25	2/149	<0.0001
GIS (z score)	-0.922 (0.141) <sup>B,C</sup>	0.136 (0.091) <sup>A,C</sup>	0.663 (0.157) <sup>A,B</sup>	31.70	2/149	<0.0001
Cognitive disorders (z score)	-0.530 (0.162) <sup>B,C</sup>	0.145 (0.105) <sup>A</sup>	0.197 (0.181) <sup>A</sup>	6.93	2/149	0.002

Table 2. Clinical rating scales scores in control participants (CP) and Long COVID (LC) patients divided according to their TO2 index.

All results of univariate GLM analysis; data are expressed as mean (SE), i.e. estimated marginal means obtained by GLM analysis after covarying for age, sex, education and smoking.

CP: control participants, FF: Fibro fatigue scale, HAMA: Hamilton Anxiety Rating Scale, HAMD: Hamilton Depression Rating Scale.

Physiosom: physiosomatic, GIS: gastro-intestinal

Physio-affective core: first factor score extracted from pure and physiosom HAMD/HAMA and pure FF scores

Features	FA#1	Features	FA#2
TO2 index	0.898	TO2 index	0.937
SpO2	-0.821	SpO2	-0.819
Body temperature	0.721	Body temperature	0.766
Pure HAMD	0.703	Chronic fatigue	0.750
Physiosom HAMD	0.809	GIS	0.674
Pure HAMA	0.662	Sleep	0.693
Physiosom HAMA	0.882	Autonomic	0.854
Pure FF	0.877		
КМО	0.772	КМО	0.712
% Variance	64.19%	% Variance	62.29%
Cronbach alpha	0.784	Cronbach alpha	0.704

Table 3: Results of factor analysis (FA) conducted on body temperature, oxygen saturation (SpO<sub>2</sub>) and clinical rating scales

KMO: Keiser-Meier-Olkin test, SpO2: Oxygen saturation, FF: Fibro-fatigue scale, HAMD: Hamilton Depression Rating Scale, HAMA: Hamilton Anxiety Rating Scale. TO2 index: computed as z body temperature – z SpO2.

Dependent	Explanatory Variables	Coeffi	cients of input	variables	Model statistics			
Variables		β	t	р	<b>R</b> <sup>2</sup>	F	df	р
#1. Pure HAMD	Model				0.389	23.67	4/149	< 0.001
	Body temperature	0.387	4.86	< 0.001				
	SpO2	-0.268	-3.36	< 0.001				
	Education	-0.146	-2.25	0.026				
	Age	-0.135	-2.10	0.038				
#2. Physiosom	Model				0.427	37.20	3/150	< 0.001
HAMD	spO2	-0.468	-6.02	< 0.001				
	Body temperature	0.220	2.85	0.005				
	AstraZeneca or Pfizer	0.155	2.47	0.015				
#3. Pure HAMA	Model				0.339	25.68	3/150	< 0.001
	spO2	-0.511	-7.58	< 0.001				
	Female sex	0.217	3.26	0.001				
	AstraZeneca	0.134	1.98	0.049				
#4. Physiosom	Model				0.566	48.51	4/149	< 0.001
HAMA	spO2	-0.565	-8.31	< 0.001				
	Body temperature	0.228	3.38	< 0.001				
	AstraZeneca or Pfizer	0.134	2.45	0.015				
	Female Sex	0.120	2.22	0.028				
<b>#5. Pure FF</b>	Model				0.549	91.91	2/151	< 0.001
	SpO2	-0.515	-7.60	< 0.001				
	Body temperature	0.309	4.57	< 0.001				
#6. Physio-affective	Model				0.607	57.64	4/149	< 0.001
phenome score	SpO2	-0.565	-8.72	< 0.001				
	Body temperature	0.273	4.25	< 0.001				
	Female sex	0.115	2.23	0.027				

**Table 4:** Results of multiple regression analyses with psychiatric rating scales and subdomain scores as dependent variables.


AstraZeneca or Pfizer	0.112	2.15	0.033				
-----------------------	-------	------	-------	--	--	--	--

SPO<sub>2</sub>: Oxygen saturation, FF: Fibro-Fatigue scale, HAMA: Hamilton Anxiety Rating Scale, HAMD: Hamilton Depression Rating Scale; Physioaffective phenome score: first factor score extracted from pure and physiosom HAMD/HAMA and pure FF scores **Table 5.** Results of canonical correlation analyses examining the effects of body temperature and oxygen saturation (SpO2) on the mental andphysiological symptoms of Long COVID


	HAMD		FF	FF		A
Feature sets	re sets Variables C Loadings Variables C 1		C Loadings	variable	C Loadings	
	Depressed mood	0.672	Muscle pain	0.882	Anxious mood	0.583
	Insomnia early	0.674	Muscle tension	0.744	Tension	0.759
	Insomnia middle	0.818	Fatigue	0.835	Insomnia	0.684
	Somatic GIS	0.681	Irritability	0.653	Depressed mood	0.635
Set 1 Clinical	Genital symptoms	0.858	Sleep	0.652	Sensory	0.627
	Hypochondriasis	0.729	Autonomic	0.802	Respiratory	0.878
			GIS	0.577	Genitourinary	0.723
			Headache	0.747	Autonomic	0.858
			Malaise	0.613		
Set 2	Body temperature	0.7675	Body temperature	0.787	Body temperature	0.749
Biomarkers	SpO2	-0.971	SpO2	-0.963	SpO2	-0.977
Statistics	F (df)	14.07 (12/292)		11.06 (18/286)		15.59 (16/288)

р	<0.001	<0.001	<0.001
Correlation	0.750	0.771	0.807
Set 1 by set 2	0.310	0.319	0.343
Set 1 by self	0.551	0.537	0.526
Set 2 by self	0.766	0.773	0.758


C Loadings: Canonical Loadings, GIS: gastro-intestinal symptoms, HAMD: Hamilton Depression Rating Scale; FF: Fibro-fatigue scale; HAMA: Hamilton Anxiety Rating Scale




**Figure 1**. Partial regression of the physio-affective phenome score in controls and patients with Long COVID (LC) on oxygen saturation levels



**Figure 2**. Partial regression of the physio-affective phenome score in controls and patients with Long COVID (LC) on peak body temperature



**Figure 3**. Partial regression of the physio-affective phenome score in controls and patients with Long COVID (LC) on the TO2 index, which combines higher body temperature and lower oxygen saturation



**Figure 4**. Partial regression of the physio-affective phenome score in patients with Long COVID (LC) on the TO2 index during acute COVID-19, which combines higher body temperature and lower oxygen saturation